title: Plasmatic ADAMTS-13 metalloprotease and von Willebrand factor in children with cyanotic congenital heart disease.
abstract: Changes in plasma von Willebrand factor concentration (VWF:Ag) and ADAMTS-13 activity (the metalloprotease that cleaves VWF physiologically) have been reported in several cardiovascular disorders with prognostic implications. We therefore determined the level of these proteins in the plasma of children with cyanotic congenital heart disease (CCHD) undergoing surgical treatment. Forty-eight children were enrolled (age 0.83 to 7.58 years). Measurements were performed at baseline and 48 h after surgery. ELISA, collagen-binding assays and Western blotting were used to estimate antigenic and biological activities, and proteolysis of VWF multimers. Preoperatively, VWF:Ag and ADAMTS-13 activity were decreased (65 and 71% of normal levels considered as 113 (105-129) U/dL and 91 ± 24% respectively, P < 0.003) and correlated (r = 0.39, P = 0.0064). High molecular weight VWF multimers were not related, suggesting an interaction of VWF with cell membranes, followed by proteolytic cleavage. A low preoperative ADAMTS-13 activity, a longer activated partial thromboplastin time and the need for cardiopulmonary bypass correlated with postoperative bleeding (P < 0.05). Postoperatively, ADAMTS-13 activity increased but less extensively than VWF:Ag (respectively, 2.23 and 2.83 times baseline, P < 0.0001), resulting in an increased VWF:Ag/ADAMTS-13 activity ratio (1.20 to 1.54, respectively, pre- and postoperative median values, P = 0.0029). ADAMTS-13 consumption was further confirmed by decreased ADAMTS-13 antigenic concentration (0.91 ± 0.30 to 0.70 ± 0.25 µg/mL, P < 0.0001) and persistent proteolysis of VWF multimers. We conclude that, in pediatric CCHD, changes in circulating ADAMTS-13 suggest enzyme consumption, associated with abnormal structure and function of VWF.
authors.affiliation: Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, SP, Brasil.
authors.forename: R P S
authors.initials: RP
authors.lastname: Soares
authors.forename: S P
authors.initials: SP
authors.lastname: Bydlowski
authors.forename: N M
authors.initials: NM
authors.lastname: Nascimento
authors.forename: A M
authors.initials: AM
authors.lastname: Thomaz
authors.forename: E N M
authors.initials: EN
authors.lastname: Bastos
authors.forename: A A
authors.initials: AA
authors.lastname: Lopes
mesh_terms: D051722:ADAM Proteins / Q000097:blood*; D000071120:ADAMTS13 Protein; D015415:Biomarkers / Q000097:blood; D015153:Blotting, Western; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D006330:Heart Defects, Congenital / Q000097:blood* / Q000601:surgery; D006801:Humans; D007223:Infant; D011237:Predictive Value of Tests; D014841:von Willebrand Factor / Q000032:analysis*
chemical_list: D015415:Biomarkers; D014841:von Willebrand Factor; D051722:ADAM Proteins; D000071120:ADAMTS13 Protein; C099604:ADAMTS13 protein, human
references.citation: Thromb Haemost. 2007 Jan;97(1):21-6
references.pmid: 17200766
references.citation: Blood. 2001 Nov 1;98(9):2730-5
references.pmid: 11675345
references.citation: Thromb Haemost. 2009 Feb;101(2):239-47
references.pmid: 19190805
references.citation: Atherosclerosis. 2009 Nov;207(1):250-4
references.pmid: 19439298
references.citation: FEBS Lett. 2007 Apr 17;581(8):1631-4
references.pmid: 17383642
references.citation: J Clin Invest. 1987 Jan;79(1):117-23
references.pmid: 3491837
references.citation: J Thromb Haemost. 2005 Feb;3(2):397-9
references.pmid: 15670057
references.citation: Circulation. 2000 Sep 12;102(11):1290-5
references.pmid: 10982545
references.citation: Br J Haematol. 1987 Oct;67(2):193-7
references.pmid: 3499929
references.citation: Thromb J. 2007 Sep 25;5:14
references.pmid: 17894864
references.citation: Lab Invest. 2005 Jun;85(6):780-8
references.pmid: 15806136
references.citation: Blood. 1990 Feb 1;75(3):688-95
references.pmid: 2105107
references.citation: Int J Mol Med. 1999 Dec;4(6):575-83
references.pmid: 10567665
references.citation: J Immunol. 1989 Jun 1;142(11):3993-9
references.pmid: 2497185
references.citation: Haemophilia. 1998;4 Suppl 3:15-24
references.pmid: 10028314
references.citation: J Thorac Cardiovasc Surg. 1996 May;111(5):982-7
references.pmid: 8622323
references.citation: Ann Thorac Surg. 1997 Feb;63(2):482-8
references.pmid: 9033324
references.citation: J Thromb Haemost. 2006 Jun;4(6):1396-404
references.pmid: 16706987
references.citation: J Thromb Haemost. 2008 Jul;6(7):1233-5
references.pmid: 18433458
references.citation: J Mol Med (Berl). 2002 Oct;80(10):639-47
references.pmid: 12395148
references.citation: Thromb Haemost. 2000 Jan;83(1):54-9
references.pmid: 10669155
references.citation: J Thromb Haemost. 2007 Nov;5(11):2284-90
references.pmid: 17764538
references.citation: Thromb Haemost. 2010 Feb;103(2):408-14
references.pmid: 20024494
references.citation: J Thromb Haemost. 2008 Apr;6(4):583-8
references.pmid: 18194418
references.citation: Blood. 1995 Jun 1;85(11):3164-72
references.pmid: 7756649
references.citation: Thromb Res. 2009 May;124(1):75-9
references.pmid: 19162307
references.citation: Blood. 2005 Feb 1;105(3):1085-93
references.pmid: 15388580
references.citation: Thromb Haemost. 2009 Feb;101(2):305-11
references.pmid: 19190814
references.citation: Br J Haematol. 2007 Aug;138(4):534-40
references.pmid: 17608762
references.citation: Blood. 2005 Aug 1;106(3):922-4
references.pmid: 15855280
references.citation: Braz J Med Biol Res. 2002 Nov;35(11):1259-63
references.pmid: 12426624
references.citation: Thromb Haemost. 2002 Oct;88(4):598-604
references.pmid: 12362230
references.citation: Expert Rev Cardiovasc Ther. 2006 Nov;4(6):813-25
references.pmid: 17173498
references.citation: J Clin Invest. 1996 Jan 15;97(2):493-500
references.pmid: 8567972
references.citation: Am J Cardiol. 2006 Jul 15;98(2):254-8
references.pmid: 16828603